Skip to main content
Premium Trial:

Request an Annual Quote

NEWSBRIEF: Novartis, Variagenics Ink Prostate-Cancer Pharmacogenomics Deal

NEW YORK, May 2 - Variagenics said today it will study the pharmacogenomics of two of Novartis' prostate-cancer drug candidates.

 

Variagenics will use its platform to identify drug-efficacy markers for two compounds, Gleevec and PKI 166.

 

Novartis gets an exclusive license to any therapeutic markers, and Variagenics retains rights to develop DNA diagnostic tests.

 

Click here for more information.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.